Therapeutic Advancements for the Treatment of High Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life

---

ONLINE

Friday, October 27, 2023, 12:00 AM - Sunday, October 27, 2024, 12:00 AM


AMA PRA Category 1 Credits™ (1.00 hours), AAPA Category 1 CME (1.00 hours), ANCC - Nursing Contact Hour(s) (1.00 hours), Non-Physician Attendance (1.00 hours)

Myelodysplastic syndromes/myelodysplastic neoplasms, a heterogenous group of disorders of the blood-forming stem cells in the bone marrow, is associated with suboptimal numbers of one or more types of blood cells. Though relatively rare, the incidence of MDS has been steadily increasing as the average age of Americans has increased. With the recent introduction of IPSS-M only last year, clinicians on the multidisciplinary MDS team may not yet be competent with its use with differentiating low-risk versus higher-risk patients. Considering the recent changes to MDS risk assessment coupled with a multitude of promising developments, continued education is a must.

 

This activity is provided by The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL).

1. Apply updated classification guidelines in the evaluation of patients with MDS
2. Outline the role of immune surveillance and CD47 in the development of MDS
3. Discuss unmet patient needs in the treatment of HR-MDS
4. Describe the MOA of emerging therapies

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is granted to October 27, 2024. PAs should only claim credit commensurate with the extent of their participation.

The University of Texas MD Anderson Cancer Center designates this enduring material will award 1.0 Nursing Contact Hours.

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The organizing committee wishes to express appreciation to the following company for their commitment to continuing medical education by providing an educational grant in support of this educational activity:

Gilead Sciences, Inc.